Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
ACRS

ACRS - Aclaris Therapeutics Inc Stock Price, Fair Value and News

1.19USD+0.01 (+0.85%)Market Closed

Market Summary

ACRS
USD1.19+0.01
Market Closed
0.85%

ACRS Stock Price

View Fullscreen

ACRS RSI Chart

ACRS Valuation

Market Cap

84.8M

Price/Earnings (Trailing)

-1.1

Price/Sales (Trailing)

2.73

EV/EBITDA

-0.56

Price/Free Cashflow

-1.15

ACRS Price/Sales (Trailing)

ACRS Profitability

Operating Margin

89.00%

EBT Margin

-285.51%

Return on Equity

-54.4%

Return on Assets

-44.39%

Free Cashflow Yield

-86.88%

ACRS Fundamentals

ACRS Revenue

Revenue (TTM)

31.1M

Rev. Growth (Yr)

-5.14%

Rev. Growth (Qtr)

-86.35%

ACRS Earnings

Earnings (TTM)

-77.3M

Earnings Growth (Yr)

39.84%

Earnings Growth (Qtr)

-1.0K%

Breaking Down ACRS Revenue

Last 7 days

1.7%

Last 30 days

-3.2%

Trailing 12 Months

-85.3%

How does ACRS drawdown profile look like?

ACRS Financial Health

Current Ratio

6.74

Debt/Equity

0.08

Debt/Cashflow

-6.78

ACRS Investor Care

Shares Dilution (1Y)

0.83%

Diluted EPS (TTM)

-1.09

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202431.1M000
202330.8M31.2M21.4M31.2M
20226.4M6.1M23.5M29.8M
20216.9M6.6M6.8M6.8M
20204.4M5.5M6.0M6.5M
20199.7M6.9M6.8M4.2M
20182.9M6.5M6.9M9.6M
201700941.5K1.8M
201525.0K51.3K77.7K104.0K
201419.3K017.7K16.0K
201300021.0K

Tracking the Latest Insider Buys and Sells of Aclaris Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
May 01, 2024
walker neal
sold (taxes)
-3,507
1.26
-2,784
interim president and ceo
May 01, 2024
walker neal
acquired
-
-
9,467
interim president and ceo
Apr 01, 2024
walker neal
sold (taxes)
-4,062
1.26
-3,224
interim president and ceo
Apr 01, 2024
walker neal
acquired
-
-
9,467
interim president and ceo
Mar 04, 2024
powell andrew kenneth william
bought
7,500
1.25
6,000
-
Mar 02, 2024
balthaser kevin
sold (taxes)
-529
1.24
-427
chief financial officer
Mar 02, 2024
balthaser kevin
acquired
-
-
1,500
chief financial officer
Mar 02, 2024
monahan joseph
sold (taxes)
-4,378
1.24
-3,531
chief scientific officer
Mar 02, 2024
monahan joseph
acquired
-
-
12,500
chief scientific officer
Mar 01, 2024
monahan joseph
sold (taxes)
-22,012
1.24
-17,752
chief scientific officer

1–10 of 50

Which funds bought or sold ACRS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 17, 2024
Ikarian Capital, LLC
sold off
-100
-20,456
-
-%
May 16, 2024
JANE STREET GROUP, LLC
added
27.9
139,004
411,358
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-87.43
-49,679
8,658
-%
May 15, 2024
UBS ASSET MANAGEMENT AMERICAS INC
sold off
-100
-119,282
-
-%
May 15, 2024
JANUS HENDERSON GROUP PLC
sold off
-100
-21,415
-
-%
May 15, 2024
AMERIPRISE FINANCIAL INC
reduced
-2.76
10,088
78,087
-%
May 15, 2024
Lion Point Capital, LP
sold off
-100
-121,693
-
-%
May 15, 2024
BANK OF AMERICA CORP /DE/
reduced
-79.55
-99,855
31,802
-%
May 15, 2024
Octagon Capital Advisors LP
sold off
-100
-105,000
-
-%
May 15, 2024
Squarepoint Ops LLC
sold off
-100
-10,897
-
-%

1–10 of 47

Are Funds Buying or Selling ACRS?

Are funds buying ACRS calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ACRS
No. of Funds

Unveiling Aclaris Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
rock springs capital management lp
4.23%
2,998,495
SC 13G/A
Feb 14, 2024
venrock healthcare capital partners ii, l.p.
0.0%
0
SC 13G/A
Feb 14, 2024
biotechnology value fund l p
-
0
SC 13G/A
Feb 14, 2024
citadel advisors llc
6.1%
6
SC 13G/A
Feb 14, 2024
ra capital management, l.p.
0%
0
SC 13G/A
Feb 14, 2024
millennium management llc
5.3%
3,769,926
SC 13G
Feb 14, 2024
tang capital partners lp
2.5%
1,753,335
SC 13G/A
Feb 13, 2024
foresite capital fund iv, l.p.
0.0%
0
SC 13G/A
Feb 13, 2024
vanguard group inc
6.67%
4,721,887
SC 13G
Feb 08, 2024
bml investment partners, l.p.
13.3%
9,395,934
SC 13G/A

Recent SEC filings of Aclaris Therapeutics Inc

View All Filings
Date Filed Form Type Document
May 07, 2024
10-Q
Quarterly Report
May 07, 2024
8-K
Current Report
May 07, 2024
S-8
Employee Benefits Plan
May 03, 2024
4
Insider Trading
Apr 25, 2024
ARS
ARS
Apr 25, 2024
DEF 14A
DEF 14A
Apr 25, 2024
DEFA14A
DEFA14A
Apr 03, 2024
4
Insider Trading
Mar 19, 2024
8-K
Current Report
Mar 05, 2024
4
Insider Trading

Peers (Alternatives to Aclaris Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
196.9B
23.7B
11.04% 17.40%
44.73
8.29
-8.94% -35.91%
45.2B
6.7B
14.64% 19.44%
36.57
6.71
-2.81% -6.58%
44.9B
3.7B
13.71% 10.52%
51.83
12.06
8.57% 23.94%
16.0B
9.3B
13.66% 10.24%
18.95
1.73
-3.29% 6.68%
13.1B
1.2B
17.80% 114.36%
-35.76
10.81
39.26% 33.08%
12.2B
2.0B
2.71% 87.82%
38.94
6.2
25.57% 21.62%
11.4B
4.1B
-3.66% 11.24%
26.02
2.78
0.49% -11.59%
9.3B
2.5B
-20.33% -38.03%
-38.69
3.67
15.21% 53.51%
MID-CAP
3.1B
603.7M
54.73% -14.09%
-6.73
5.14
25.21% 30.68%
2.9B
929.2M
11.70% -18.80%
1.9K
3.16
28.93% 111.61%
SMALL-CAP
808.3M
275.1M
87.44% 103.94%
-4.41
2.94
-13.93% -126.97%
84.8M
31.1M
-3.25% -85.34%
-1.1
2.73
0.95% 19.75%
33.0M
9.2M
-24.07% -37.65%
-2.24
3.6
11.85% 45.80%
2.5M
5.5M
-62.31% 120.18%
-0.2
0.45
-68.52% -141.15%
183.8K
25.9M
-50.00% -94.83%
-0.01
0.01
-57.78% -93.11%

Aclaris Therapeutics Inc News

Latest updates
MSN36 hours ago

Aclaris Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-86.4%2,398,00017,570,0009,282,0001,869,0002,528,0007,753,00019,018,0001,528,0001,453,0001,501,0001,659,0001,824,0001,777,0001,580,0001,449,0002,046,0001,407,0001,095,000983,000886,0001,263,000
Cost Of Revenue11.6%809,000725,000848,0001,042,000808,000877,000923,0001,068,0001,155,0001,149,0001,099,0001,263,0001,202,0001,286,0001,189,0001,389,0001,269,0001,027,500826,000994,0001,207,000
Costs and Expenses-1.3%21,329,00021,617,00040,859,00033,684,00032,446,00036,832,00039,892,00022,522,00020,360,00024,394,00021,954,00019,830,00030,306,00015,140,00011,914,00013,427,00016,913,00013,058,00023,847,00055,656,00028,314,000
  S&GA Expenses-100.0%-8,214,0007,091,0008,317,0008,790,0007,146,0005,813,0006,075,0006,099,0006,943,0005,979,0005,870,0004,827,0004,898,5003,859,0005,572,0006,200,0006,056,0006,838,0007,469,0007,464,000
  R&D Expenses-63.1%9,845,00026,646,00023,876,00025,275,00022,587,00021,072,00023,656,00018,779,00014,306,00014,102,00013,976,0007,897,0007,838,0008,955,5006,240,0006,466,0007,677,00010,825,50016,183,00017,519,00019,643,000
EBITDA Margin-0.4%-2.83-2.82-4.02-2.76-2.79-2.89-3.83-14.67-13.99-13.30-7.46-7.64---------
EBT Margin-0.4%-2.86-2.84-4.06-2.79-2.82-2.92-3.87-14.80-14.12-13.44-7.51-7.74---------
Net Income-1036.2%-16,941,000-1,491,000-29,261,000-29,569,000-28,160,000-27,635,000-19,952,000-20,532,000-18,789,000-22,804,000-21,146,000-18,161,000-28,754,000-13,173,000-10,659,000-11,597,000-15,586,000-18,594,000-55,319,000-49,876,000-37,565,000
Net Income Margin12.3%-2.48-2.83-5.35-3.38-3.12-2.92-3.49-13.56-12.57-13.44-11.88-10.67---------
Free Cashflow-190.9%-20,950,000-7,202,000-24,641,000-20,885,000-26,906,000-19,220,000-7,967,000-19,852,000-21,133,000-17,275,000-10,662,000-12,229,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-11.8%17419721823623025526827822725126328816171.0072.0085.0097.0098.00160217253
  Current Assets5.0%13512912313318423225725919120520624113557.0058.0071.0083.0084.00145138157
    Cash Equivalents-10.1%36.0040.0039.0031.0045.0045.0062.0068.0036.0027.0054.0011335.0022.0025.0033.0054.0036.0030.0032.0034.00
  Inventory-------------------0.000.001.00
  Net PPE-5.5%2.002.002.002.002.001.001.001.001.001.001.001.001.002.002.002.002.002.003.004.004.00
  Goodwill------------------19.00--19.00
Liabilities-20.3%32.0040.0062.0056.0053.0057.0048.0042.0046.0054.0047.0054.0049.0033.0031.0036.0039.0028.0075.0080.0071.00
  Current Liabilities-35.1%20.0031.0027.0023.0018.0022.0020.0016.0017.0023.0018.0015.0015.0015.0013.0018.0021.0022.0039.0043.0036.00
  Long Term Debt------------11.0011.0011.0011.0011.0011.00-30.0030.0030.00
Shareholder's Equity-9.6%14215715618017719822023618019721723411238.0041.0049.0058.0070.0085.00137182
  Retained Earnings-2.2%-787-770-769-740-710-682-654-634-614-595-572-551-533-504-491-480-469-453-434-379-329
  Additional Paid-In Capital0.2%930928927921888881876872795793789785646542532530527524520517512
Shares Outstanding0.5%71.0071.0071.0071.0067.0067.0065.0064.0061.0057.0061.0052.00---------
Float----713---898---915---66.00---80.00-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-207.9%-20,815-6,761-24,557-20,654-26,353-19,115-7,817-19,666-20,969-17,075-10,606-12,221-12,232-8,857-12,150-10,821-6,805-20,390-23,359-21,378-31,318
  Share Based Compensation65.0%2,0891,2665,9486,5226,8064,8134,1883,6922,3463,8513,7023,8322,6752,5041,9413,3093,4533,1813,3204,8144,862
Cashflow From Investing123.0%16,8337,55032,534-19,66225,7982,7021,217-21,22329,932-9,176-37,672-45,470-75,314-2,3055,237-10,48713,94256,43821,67318,9528,616
Cashflow From Financing-212.2%-55.0049.00-87.00--37.00-11.0072,81130.00-2.00-11,567135,871100,7507,829-278-97.0010,918-30,009-70.00-117-120
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

ACRS Income Statement

2024-03-31
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenues:  
Total revenue$ 2,398$ 2,528
Costs and expenses:  
Cost of revenue809808
Research and development9,84522,587
General and administrative6,8448,790
Licensing1,0311,061
Revaluation of contingent consideration2,800(800)
Total costs and expenses21,32932,446
Loss from operations(18,931)(29,918)
Other income, net1,9901,758
Net loss$ (16,941)$ (28,160)
Net loss per share, basic$ (0.24)$ (0.42)
Net loss per share, diluted$ (0.24)$ (0.42)
Weighted average common shares outstanding, basic71,074,85866,872,778
Weighted average common shares outstanding, diluted71,074,85866,872,778
Other comprehensive loss:  
Unrealized (loss) gain on marketable securities, net of tax of $0$ (258)$ 543
Total other comprehensive (loss) gain(258)543
Comprehensive loss(17,199)(27,617)
Contract research  
Revenues:  
Total revenue657889
Licensing  
Revenues:  
Total revenue$ 1,741$ 1,639

ACRS Balance Sheet

2024-03-31
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 35,841$ 39,878
Short-term marketable securities92,32579,228
Accounts receivable, net373298
Prepaid expenses and other current assets6,7999,452
Total current assets135,338128,856
Marketable securities33,19962,771
Property and equipment, net1,5311,620
Other assets3,9974,158
Total assets174,065197,405
Current liabilities:  
Accounts payable10,8108,878
Accrued expenses6,56519,446
Other current liabilities2,7052,628
Total current liabilities20,08030,952
Other liabilities2,9713,074
Contingent consideration9,0006,200
Total liabilities32,05140,226
Stockholders' Equity:  
Preferred stock, $0.00001 par value; 10,000,000 shares authorized and no shares issued or outstanding at March 31, 2024 and December 31, 2023
Common stock, $0.00001 par value; 200,000,000 shares authorized at March 31, 2024 and December 31, 2023; 71,248,017 and 70,894,889 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively11
Additional paidin capital930,114928,080
Accumulated other comprehensive loss(364)(106)
Accumulated deficit(787,737)(770,796)
Total stockholders' equity142,014157,179
Total liabilities and stockholders' equity$ 174,065$ 197,405
ACRS
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment offers laboratory services. The company develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. It develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an oral MK2 inhibitor for the treatment of pancreatic and metastatic breast cancer. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
 CEO
 WEBSITEaclaristx.com
 INDUSTRYDiagnostics & Research
 EMPLOYEES100

Aclaris Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Aclaris Therapeutics Inc? What does ACRS stand for in stocks?

ACRS is the stock ticker symbol of Aclaris Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aclaris Therapeutics Inc (ACRS)?

As of Fri May 17 2024, market cap of Aclaris Therapeutics Inc is 84.81 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ACRS stock?

You can check ACRS's fair value in chart for subscribers.

What is the fair value of ACRS stock?

You can check ACRS's fair value in chart for subscribers. The fair value of Aclaris Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Aclaris Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ACRS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Aclaris Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether ACRS is over valued or under valued. Whether Aclaris Therapeutics Inc is cheap or expensive depends on the assumptions which impact Aclaris Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ACRS.

What is Aclaris Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, ACRS's PE ratio (Price to Earnings) is -1.1 and Price to Sales (PS) ratio is 2.73. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ACRS PE ratio will change depending on the future growth rate expectations of investors.